Cosibelimab | Interleukin Related interleukin-related.com

Product Name :
Cosibelimab

Search keywords :
Cosibelimab

drugId :
null

Target Vo:
Programmed death-ligand 1

Target Vo Short Name :
PD-L1

Moa_Name:
Programmed death-ligand 1 blockers

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Dana-Farber Cancer Institute

Active Company_Name :
Checkpoint Therapeutics Inc

Active Indication_Name:
Carcinoma, Squamous Cell

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
NDA/BLA

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
GLP-1R Antibody
Epac1 Antibody
Phospho-PDGFR beta (Y740) Antibody: Phospho-PDGFR beta (Y740) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 124 kDa, targeting to Phospho-PDGFR beta (Y740). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Rat.

Author: Interleukin Related

Related Posts